Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 12 Dec 2021
Reviewer:  Yoshihiro Kakeji
Reviewer's report:
The authors  aimed to evaluate the predictive value of pre-treatment SII-PNI score on the
sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with
locally advanced gastric cancer. The pre-treatment SII-PNI score is a significant indicator
for predicting chemosensitivity of locally advanced patients after sintilimab immunotherapy
combined with XELOX chemotherapy. Although this study showed some results, which was
like putting a fifth wheel on a coach. SII, PNI, and SII-PNI score, too many parameters.
1. What difference is there among SII, PNI, and SII-PNI score?
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 12 Dec 2021
Reviewer:  Yoshihiro Kakeji
Reviewer's report:
The authors  aimed to evaluate the predictive value of pre-treatment SII-PNI score on the
sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with
locally advanced gastric cancer. The pre-treatment SII-PNI score is a significant indicator
for predicting chemosensitivity of locally advanced patients after sintilimab immunotherapy
combined with XELOX chemotherapy. Although this study showed some results, which was
like putting a fifth wheel on a coach. SII, PNI, and SII-PNI score, too many parameters.
1. What difference is there among SII, PNI, and SII-PNI score?
Please review this paper.
user
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 12 Dec 2021
Reviewer:  Yoshihiro Kakeji
Reviewer's report:
The authors  aimed to evaluate the predictive value of pre-treatment SII-PNI score on the
sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with
locally advanced gastric cancer. The pre-treatment SII-PNI score is a significant indicator
for predicting chemosensitivity of locally advanced patients after sintilimab immunotherapy
combined with XELOX chemotherapy. Although this study showed some results, which was
like putting a fifth wheel on a coach. SII, PNI, and SII-PNI score, too many parameters.
1. What difference is there among SII, PNI, and SII-PNI score?
assistant